This report provides an overview of the most common diagnostic methods that bring to light incidental findings of pancreatic cancer.It reviews the impact of medical imaging and genetic assessment on the definitions of...This report provides an overview of the most common diagnostic methods that bring to light incidental findings of pancreatic cancer.It reviews the impact of medical imaging and genetic assessment on the definitions of incidental findings and incidentaloma of the pancreas.For different diagnostic approaches(eg,MRI and CT)and for different affections(cysts/intraductal papillary mucinous neoplasia,solid lesions),specific guidelines have been proposed and some are established.Based on this,we summarise the differences between the traditional methods with those applied in the PANCAID project.Biomarkers,genetic predispositions,mutations and circulating tumour cells give rise to different levels of concern.The final part of the report discusses the risks and the opportunities associated with further diagnostic procedures and surgical interventions.From the ethical perspective,the most urging question is,can a screening based on liquid biopsy and blood samples open a gateway for the prevention of pancreatic cancer—even if morbidity and lethality of today’s surgical interventions is still very high?展开更多
基金Funded by the European Union,PANCAIM(101016851)on the early detection of pancreatic cancer and PANCAID(101096309)on the use of liquid biopsy。
文摘This report provides an overview of the most common diagnostic methods that bring to light incidental findings of pancreatic cancer.It reviews the impact of medical imaging and genetic assessment on the definitions of incidental findings and incidentaloma of the pancreas.For different diagnostic approaches(eg,MRI and CT)and for different affections(cysts/intraductal papillary mucinous neoplasia,solid lesions),specific guidelines have been proposed and some are established.Based on this,we summarise the differences between the traditional methods with those applied in the PANCAID project.Biomarkers,genetic predispositions,mutations and circulating tumour cells give rise to different levels of concern.The final part of the report discusses the risks and the opportunities associated with further diagnostic procedures and surgical interventions.From the ethical perspective,the most urging question is,can a screening based on liquid biopsy and blood samples open a gateway for the prevention of pancreatic cancer—even if morbidity and lethality of today’s surgical interventions is still very high?
